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Introduction {#sec1}
============

Appropriate self-renewal and differentiation of adult stem cells are essential for tissue homeostasis and are tightly controlled by various cellular and molecular mechanisms, including the dynamic regulation of chromatin structure by ATP-dependent chromatin-remodeling complexes ([@bib14], [@bib30]). These remodelers use energy produced from ATP hydrolysis to configure nucleosomal positioning and modulate DNA accessibility. Such a process ensures fidelity of crucial gene-expression programs during developmental processes such as lineage specification. In support of this pathway contributing to cell fate determination, somatic mutation of chromatin remodeler genes is common in human disease, including cancer ([@bib14], [@bib30]).

Bromodomain PHD finger transcription factor (BPTF) is a core and largest component of the conserved, multi-subunit nucleosome remodeling factor (NURF) complex ([@bib17], [@bib26]). NURF loosens condensed chromatin to promote DNA accessibility and target gene activation ([@bib26], [@bib27], [@bib35]). While global knockout of *Bptf* in mice leads to lethality on embryonic day 8.5, demonstrating its requirement for early development ([@bib17]), clinical studies reveal loss-of-function mutation of *BPTF* in individuals with syndromic neurodevelopmental anomalies ([@bib29]). Furthermore, BPTF was recently shown to be critical for the maintenance or differentiation of mammary gland stem cells ([@bib10]), melanocytes ([@bib7], [@bib19]), and T cells ([@bib18], [@bib34]). BPTF contains two motifs in its C terminus, a PHD finger and a bromodomain that bind to histone H3 lysine 4 trimethylation (H3K4me3) and histone acetylation, respectively ([@bib6], [@bib26], [@bib35]). Deposition of these two modifications occurs partly via the histone methyltransferase MLL/KMT2A and associated histone acetyltransferases ([@bib9]). While previous works detail the essential role for KMT2A in regulation of hematopoietic and neuronal stem cells ([@bib2], [@bib13], [@bib20]), the specific contributions of BPTF remain undefined in this process.

Using knockout mice, we here show BPTF as a crucial chromatin regulator of hematopoietic stem cells (HSCs). Reconstitution assays demonstrate that *Bptf-*null HSCs exhibited the decreased repopulating capacity, causing severe hematopoietic defects. Our genomic profiling shows that ablation of BPTF in hematopoietic stem/progenitor cells (HSPCs) leads to decreased expression of an HSC-specific gene-expression program, which includes a master transcription factor (TF) regulatory node (*Meis1*, *Pbx1*, *Mn1*, and *Lmo2*) known to be crucial for HSC self-renewal and function. We also find that BPTF potentiates the chromatin accessibility of these HSC TF genes. Collectively, our results support a vital requirement of the BPTF chromatin remodeler for the maintenance of adult HSPCs and for the activation of a gene transcription program essential for HSC functions.

Results {#sec2}
=======

Maintenance of Adult HSPCs, Including Long-Term HSCs, Requires *Bptf* Expression {#sec2.1}
--------------------------------------------------------------------------------

Using transcriptome datasets of hematopoiesis ([@bib4], [@bib28]), we found *Bptf* preferentially expressed in the primitive HSPC compartment ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). To study the role of BPTF in HSPCs, we produced inducible knockout mice (*Bptf*^*flf*^;*Mx1-*cre) designed to ablate *Bptf* from the bone marrow (BM) upon activation of *Mx1*-cre by polyinosinic-polycytidylic acid (pIpC). We verified efficient deletion (\>95%) of *Bptf* in the BM (i.e., *Bptf*^*cKO*^) via genotyping and RT-PCR to confirm our model ([Figures 1](#fig1){ref-type="fig"}B and 1C). While *Mx1*-cre is widely used for achieving inducible gene deletion in HSPC, it is also associated with pIpC-caused interferon activation and cre-induced potential toxicity. To address these issues, we produced littermate controls with *Bptf*^*flf*^ or *Mx1-*cre alone and subjected them to pIpC administration. By fluorescence-activated cell sorting (FACS) and 4 weeks after cre induction, we observed a significantly reduced total number of lineage^−^/SCA-1^+^/c-KIT^+^ (LSK) cells and long-term (LT)-HSCs (LSK/CD150^+^/CD48^−^, [Figure 1](#fig1){ref-type="fig"}D) in the BM of *Bptf*^*cKO*^ mice, relative to controls ([Figures 1](#fig1){ref-type="fig"}D and 1E). This result shows a role for BPTF in the maintenance of primitive HSPCs, including LT-HSCs, in adult mice.Figure 1Maintenance of Adult HSPCs Including LT-HSC Requires BPTF(A) *Bptf* expression in hematopoiesis (see also [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).(B and C) Genotyping (B) and RT-PCR (C; n = 3 biological replicates) confirm deletion of the *Bptf* exon 2 in total bone marrow (BM) 1 week after cre induction. w, wild-type; f, floxed; Δ, deleted (*Bptf*^*cKO*^).(D and E) FACS (D) and summary (E) of percentages of the LSK and LT-HSC cells in the BM, 4 weeks after cre induction in the *Bptf*^*cKO*^ (f/f; cre, n = 5 mice) or control littermates with *Bptf*^*f/f*^ (f/f) or *Mx1*-cre (cre) alone (n = 4 mice). Numbers in (D) indicate the percentage of gated cells. Plots in (E) are mean ± SD, with statistical analysis defined by two-tailed Student\'s t test: ns, not significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01.

BPTF Sustains the Self-Renewal and Repopulating Capacity of HSCs in a Cell-Autonomous Mechanism {#sec2.2}
-----------------------------------------------------------------------------------------------

Next, we sought to determine whether BPTF regulates HSC function in a cell-autonomous manner. Using a colony-forming assay with sorted LSK populations, we found that *Bptf*-ablated cells produced significantly fewer and smaller colonies relative to control ([Figures 2](#fig2){ref-type="fig"}A and 2B). Similar results were seen in LSK cells with short hairpin RNA-mediated knockdown of *Bptf* ([Figure S1](#mmc1){ref-type="supplementary-material"}C). We also performed competitive bone marrow transplantation (BMT) to test the reconstitution capacity of *Bptf*-null HSCs. Here, total BM cells from CD45.2^+^, *Bptf*^*f/f*^;*Mx1-*cre^+^ mice were mixed at a 1:1 ratio with wild-type competitor cells from CD45.1^+^ mice, then used as donor for BMT to lethally irradiated recipients ([Figure 2](#fig2){ref-type="fig"}C). Cells from *Bptf*^*f/f*^ or heterozygous *Bptf*^*f/w*^;*Mx1*-cre^+^ mice were used as control in BMT. When we observed stable chimerism in all cohorts 8 weeks after BMT ([Figure 2](#fig2){ref-type="fig"}D), we induced *Bptf* deletion and observed a gradual decline in the contribution of the *Bptf-*null donor cells to peripheral blood ([Figures 2](#fig2){ref-type="fig"}D and 2E). Meanwhile, the percentages of control donor cells remained stable after pIpC injection, suggesting that one *Bptf* allele is sufficient to sustain HSC function and hematopoiesis ([Figures 2](#fig2){ref-type="fig"}D and 2E).Figure 2BPTF Is Essential for the Maintenance and Reconstitution Function of HSCs in a Cell-Autonomous Manner(A and B) Summary (A) and representative colony (B; scale bar, 1 mm) in colony-forming unit assays with 300 of the *Bptf*^*f/f*^ or *Bptf*^*cKO*^ (f/f; cre) LSK cells sorted 7 days after cre induction (n = 3 independent experiments; ^∗^p \< 0.05; ^∗∗^p \< 0.01; see also [Figure S1](#mmc1){ref-type="supplementary-material"}C).(C) Outline of competitive reconstitution assay via BMT.(D) Percentage of donor-derived CD45.2^+^ cells from *Bptf*^*cKO*^ (blue; n = 8 mice) and control mice, either *Bptf*^*f/f*^ (red; n = 8) or *Bptf*^*-/w*^ (green; n = 6), in peripheral blood of recipients at the indicated time points. Error bars denote SE.(E) FACS of donor-derived CD45.2^+^ cells, either from *Bptf*^*f/f*^ or *Bptf*^*cKO*^ mice, in peripheral blood 5 weeks after cre induction.(F--H) Summary (F and G; n = 2 mice at each time point) and FACS (H) of donor-derived CD45.2^+^ cells, either from control (*Bptf*^*f/f*^) or *Bptf*^*cKO*^ mice, in the BM LSK and LT-HSC populations 8 weeks after cre induction (see also [Figure S1](#mmc1){ref-type="supplementary-material"}D).(I and J) Percentage (I; n = 4 mice) and FACS (J) of donor-derived CD45.2^+^ cells from *Bptf*^*f/f*^ or *Bptf*^*cKO*^ mice in the indicated BM populations 8 weeks after cre induction (see also [Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).

We also examined the LSK and LT-HSC populations in recipients in the reconstitution assay ([Figure S1](#mmc1){ref-type="supplementary-material"}D), and found a significantly decreased contribution of *Bptf*^*cKO*^ but not control donor cells to these primitive compartments ([Figures 2](#fig2){ref-type="fig"}F and 2G). Eight weeks after cre induction, the presence of *Bptf-*ablated donors decreased to nearly undetectable levels in HSCs and differentiated cell compartments in the BM or spleen ([Figures 2](#fig2){ref-type="fig"}H--2J, [S1](#mmc1){ref-type="supplementary-material"}E, and S1F). Loss of the *Bptf*^*cKO*^ HSCs may occur through failure to maintain HSPCs\' cell identity, increased apoptosis, or their combination. We assessed LSK cells 3 weeks after cre induction and did not detect a significant increase in apoptosis in *Bptf*^*cKO*^ mice relative to control ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). Together, these results show a cell-autonomous role of BPTF in sustaining the repopulating function of HSCs.

BPTF Activates an HSC-Specific Gene-Expression Program, Including a "Stemness" Regulatory Node that Comprises Several Master Regulators of HSCs {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------

To define the gene-regulatory role of BPTF in HSPCs, we performed RNA sequencing (RNA-seq) to profile transcriptomes of the LSK cells sorted from *Bptf*^*cKO*^ and *Bptf*^*f/f*^ mice 10 days after cre induction ([Figure S2](#mmc1){ref-type="supplementary-material"}A). As expected, there was a lack of RNA-seq reads mapped to the *Bptf* exon 2 in *Bptf*^*cKO*^ cells due to cre-mediated deletion ([Figure 3](#fig3){ref-type="fig"}A). This produced the out-of-frame unstable *Bptf* transcripts, with reduced overall expression when compared with control ([Figure 3](#fig3){ref-type="fig"}B, *Bptf*). *Bptf*^*cKO*^ and *Bptf*^*f/f*^ LSK cells expressed comparable levels of *cKit*, an LSK marker ([Figure 3](#fig3){ref-type="fig"}B, *cKit*), and comparison of their RNA-seq profiles identified 407 downregulated and 230 upregulated transcripts due to *Bptf* ablation (with adjusted p \< 0.05 and fold change \> 1.5; [Figure 3](#fig3){ref-type="fig"}B \[inset\] and [Table S1](#mmc2){ref-type="supplementary-material"}). Gene ontology (GO) and Ingenuity Pathway Analysis revealed the transcription regulation and cell adhesion-related pathways among the most downregulated ones upon BPTF loss ([Figures 3](#fig3){ref-type="fig"}C and 3D), including a TF regulatory node that consists of *Meis1*, *Pbx1*, *Mn1*, and *Lmo2* ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Previous studies show these TFs as master regulators of HSC by establishing the gene-regulatory circuits essential for HSC self-renewal and identity ([@bib12], [@bib31], [@bib33]). Consistently, when we related our RNA-seq data to the previously reported HSC gene sets by gene set enrichment analysis (GSEA), we found that, relative to *Bptf*^*cKO*^, *Bptf*^*f/f*^ LSK cells are enriched with LSK signature genes ([@bib5], [@bib16]) and those sustained by a crucial HSC regulator, KMT2A ([@bib2]) ([Figures 3](#fig3){ref-type="fig"}E--3G). Also, the AP1 complex TFs (e.g., *Fos* and *Jun*) showed decreased expression in *Bptf*^*cKO*^ LSK cells ([Figure 3](#fig3){ref-type="fig"}D, left). GO and GSEA also found the biosynthesis- and translation-related pathways among the most upregulated ones in *Bptf*^*cKO*^ cells ([Figures 3](#fig3){ref-type="fig"}H and [S2](#mmc1){ref-type="supplementary-material"}C--S2E), a phenomenon similar to that reported in the *KMT2A-*null HSPCs ([@bib2]). The most upregulated genes include many aminoacyl-tRNA synthetase and solute carrier protein genes ([Figure 3](#fig3){ref-type="fig"}D, right). By RT-PCR, we validated downregulation of *Pbx1*, *Meis1*, *Mn1*, and *Lmo2* upon *Bptf* loss in LSK cells, while expression of *Myc*, *cKit*, and *Cd34* was unchanged ([Figure 3](#fig3){ref-type="fig"}I). Thus, we identified a BPTF-dependent gene-expression program that includes several master TFs of HSCs, which supports a role of BPTF in defining HSCs\' cellular identity.Figure 3RNA-Seq Profiling Identifies a BPTF-Dependent Gene-Activation Program that Includes Several Key Master Regulators of HSCs(A) IGV view showing the RNA-seq profile of *Bptf* in the *Bptf*^*f/f*^ and *Bptf*^*cKO*^ (f/f; cre) LSK cells after pIpC treatment. For cross-sample comparison, the scale of profile is normalized with total sequencing read counts.(B) The MA plot of RNA-seq transcriptome profiles in the *Bptf*^*cKO*^ versus *Bptf*^*f/f*^ LSK cells after pIpC treatment. The x axis shows the average gene expression (log~2~-transformed) in control and knockout samples, while the y axis shows the indicated fold change by log~2~ transformation. Each dot represents a gene. The red and green colors mark genes that show significant differential expression, with a cutoff of adjusted p value (padj) \< 0.05 and absolute log~2~(fold change) \> 0.43. An inserted table summarizes the total number of transcripts found up- or downregulated in *Bptf*^*cKO*^ LSK cells relative to *Bptf*^*f/f*^ controls, with the indicated cutoff of fold change (FC) and padj (see also [Figure S2](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc2){ref-type="supplementary-material"}).(C) GO analysis reveals the indicated gene pathway among the transcripts downregulated in *Bptf*^*cKO*^ LSK cells relative to *Bptf*^*f/f*^ controls (see also [Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).(D) RNA-seq identifies genes downregulated (left; green) or upregulated (right; red) in *Bptf*^*cKO*^ LSK cells, relative to *Bptf*^*f/f*^ controls. Base Mean denotes the average RNA-seq count.(E--H) GSEA reveals enrichment of the indicated signature, either LSK "stemness" genes (E and F), a KMT2A-sustained gene network (G), or ribosomal genes (H) in *Bptf*^*cKO*^ versus *Bptf*^*f/f*^ LSK cells after cre induction (see also [Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E).(I) qRT-PCR using the *Bptf*^*cKO*^ versus *Bptf*^*f/f*^ LSK cells sorted on day 10 after cre induction. Data are mean ± SD (n = 3 biological replicates) and normalized to *β-actin* and *Bptf*^*f/f*^ cells. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

BPTF Potentiates DNA Accessibility at the HSC "Stemness" Genes {#sec2.4}
--------------------------------------------------------------

To test whether BPTF directly targets the "stemness" genes identified by RNA-seq, we assessed BPTF binding by chromatin immunoprecipitation (ChIP). We used HPC-7 cells because ChIP requires large cell numbers, which prevents the use of primary HSPCs, and HPC-7 cells were previously used as an HSPC mimic to map the genomic binding of HSC regulators ([@bib33]). ChIP-sequencing (ChIP-seq) analysis revealed high H3K4me3 at the promoters of "stemness" genes such as *Meis1*, *Pbx1*, and *Lmo2* ([Figures 4](#fig4){ref-type="fig"}A--4C and [S3](#mmc1){ref-type="supplementary-material"}A, top panel), providing a putative platform for BPTF binding. Unfortunately, BPTF ChIP-seq failed due to inadequate pull-down of DNA, but conventional ChIP-qPCR showed significant binding of BPTF to the tested promoter loci at "stemness" genes, compared with the negative control ([Figure 4](#fig4){ref-type="fig"}D). Because BPTF/NURF modulates nucleosomal positioning, we also used the assay for transposase-accessible chromatin followed by sequencing (ATAC-seq) to measure DNA accessibility in *Bptf*^*cKO*^ versus *Bptf*^*f/f*^ LSK cells after cre induction ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Upon *Bptf* ablation, we did not see a dramatic change in global ATAC-seq signals ([Figure S3](#mmc1){ref-type="supplementary-material"}C) but observed significantly reduced DNA accessibility at the promoters of downregulated genes ([Figure 4](#fig4){ref-type="fig"}E) such as *Meis1*, *Pbx1*, *Fos*, and *Lmo2* ([Figures 4](#fig4){ref-type="fig"}A--4C and [S3](#mmc1){ref-type="supplementary-material"}A). We also observed decreased ATAC-seq signals at putative distal or intragenic enhancers of these TF genes ([Figures 4](#fig4){ref-type="fig"}A--4C and [S3](#mmc1){ref-type="supplementary-material"}A). Together, these genomic data support crucial roles of BPTF in potentiating DNA accessibility and appropriate expression of key HSC TF genes. Further work is needed to firmly define genomic binding of BPTF in HSPCs.Figure 4BPTF Potentiates Chromatin Accessibility at HSC "Stemness" Genes(A--C) ChIP-seq profiles of H3K4me3 and input at the indicated genes in HPC-7 cells, and their ATAC-seq profiles in *Bptf*^*f/f*^ versus *Bptf*^*cKO*^ LSK cells 7 days after cre induction. For cross-sample comparison, the scales of profiles are normalized with total sequencing read counts (see also [Figure S3](#mmc1){ref-type="supplementary-material"}A).(D) BPTF ChIP at the indicated gene promoter in HPC-7 cells. Fold of enrichment in signals, shown as mean ± SD (n = 3 biological replicates), was normalized to input and to a control locus (Chr8_Int). ^∗^p \< 0.05; ^∗∗^p \< 0.01.(E) Comparison of ATAC-seq data in *Bptf*^*cKO*^ versus *Bptf*^*f/f*^ LSK cells shows a significant reduction of ATAC-seq signals at the promoters of genes showing downregulation due to BPTF loss, relative to genome background. Plotted at y axis are log~2~-transformed ratios of promoter-associated ATAC-seq reads between two samples, either at all genes (left) or at the top 500 downregulated genes in *Bptf*^*cKO*^ LSK cells (right), relative to *Bptf*^*f/f*^ control (see also [Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C).(F and G) Total cell numbers in the femur (F) and the size of spleen (G) in *Bptf*^*f/f*^ (n = 3) versus *Bptf*^*cKO*^ (n = 4) mice 4 weeks after cre induction. ^∗^p \< 0.05; ^∗∗^p \< 0.01.(H--J) Complete blood counts of peripheral blood collected from *Bptf*^*cKO*^ mice (n = 4) and *Bptf*^*f/f*^ littermates (n = 4): WBC, white blood cells (H); RBC, red blood cells (I); and platelets (J) (see also [Figure S4](#mmc1){ref-type="supplementary-material"}). ^∗∗∗^p \< 0.001.

Hematopoietic-Specific Loss of BPTF Leads to Bone Marrow Failure, Anemia, and Leukopenia {#sec2.5}
----------------------------------------------------------------------------------------

Given the impaired function of *Bptf*^*cKO*^ HSCs, we predicted that lineage-committed populations in *Bptf*^*cKO*^ mice would be affected. Four weeks after *Bptf* deletion, the bones from *Bptf*^*cKO*^ mice appeared pale and showed significant decrease in the total BM cell number when compared with control ([Figure 4](#fig4){ref-type="fig"}F). Moreover, we observed that the *Bptf*^*cKO*^ mice possessed smaller spleens relative to control, which suggests a defect in splenic B cell development ([Figure 4](#fig4){ref-type="fig"}G). FACS of total splenic cells confirmed our observation, with a significant reduction in the B220^+^ cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Furthermore, complete blood counts revealed anemia, leukopenia, and granulocytopenia in *Bptf*^*cKO*^ mice, phenotypes that arise from the dysfunctional repopulation capacity of HSCs ([Figures 4](#fig4){ref-type="fig"}H--4J and [S4](#mmc1){ref-type="supplementary-material"}B--S4D). Thus, we show *Bptf* to be essential for normal hematopoiesis.

Discussion {#sec3}
==========

BPTF Plays an Essential Role in the Maintenance and Functionality of HSCs {#sec3.1}
-------------------------------------------------------------------------

How adult stem cells sustain themselves remains as an intriguing question. Using knockout and reconstitution systems, we showed an essential requirement of BPTF for maintaining the HSPC populations and their repopulating capacity. Mechanistically, our transcriptome profiling revealed a previously unappreciated, BPTF-dependent gene-activation program, which includes a set of master TFs known to be vital for HSC self-renewal (*Meis1*, *Pbx1*, *Mn1*, and *Lmo2*), the AP1 complex, and the MLL/KMT2A signature genes. BPTF also sustains an open chromatin state at target "stemness" genes. Thus, BPTF acts as a safeguard of adult hematopoiesis, ensuring HSCs\' reconstitution function. In support, BPTF loss caused BM failure phenotypes that are reminiscent of what was observed for *KMT2A*-null HSCs ([@bib2], [@bib13]). BPTF appears to be more crucial for blood formation under stressed conditions (e.g., reconstitution in irradiated mice) than in the steady state, a phenomenon also described in a conditional *KMT2A*-null model ([@bib21]). However, depth study is required to dissect the potentially overlapping and distinctive roles for BPTF and KMT2 in HSC self-renewal and blood formation.

BPTF Controls Vital Gene-Expression Programs to Sustain Homeostasis of Multiple Cell Lineages {#sec3.2}
---------------------------------------------------------------------------------------------

In related research, BPTF acts as a crucial regulator of mammary gland and epidermal stem cells ([@bib10], [@bib22]), melanocytes ([@bib15]), and T cells ([@bib18], [@bib34]). Here, an intriguing question is how the general chromatin regulator BPTF controls a defined yet distinct gene-expression program among different cell lineages. Presumably these cells differ in patterns of histone modifications, which can stabilize BPTF binding to genes essential for lineage definition. Also, BPTF/NURF interacts with DNA-binding factors such as CTCF ([@bib23]) and c-MYC ([@bib24]). A multivalent interaction of NURF to histone modifications, TFs, and other recruiting factors can act in concert to dictate distinct genomic targeting of BPTF/NURF.

The Essential Function of BPTF in Normal Tissue Raises a Concern on Targeting It in Cancer Therapy {#sec3.3}
--------------------------------------------------------------------------------------------------

Recently, the oncogenic role of BPTF was reported in melanoma ([@bib8], [@bib7]), pancreatic tumors, and Burkitt\'s lymphoma ([@bib25]), where BPTF was shown to promote the gene program related to tumor cell growth or survival such as c-MYC and BCL2. Bptf carries an H3K4me3-binding PHD and an acetyl-histone-binding bromodomain. Both motifs including PHD associate with human disease ([@bib3], [@bib11], [@bib32]) and can be potentially druggable ([@bib1]). BPTF was proposed as a drug target for cancer therapy ([@bib24]). However, increasing evidence now shows a vital requirement of BPTF for normal homeostasis of a range of tissues. Such broad homeostatic function for Bptf requires additional studies to address toxicity associated with targeting this protein in cancer.

Experimental Procedures {#sec4}
=======================

Details of additional procedures such as BMT, FACS, sorting, ATAC-seq, and ChIP are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Knockout Mice {#sec4.1}
-------------

CD45.2^+^ B/6 mice carrying the *Bptf*^f/f^ allele (stock \#009367) or *Mx1*-cre were purchased from the Jackson Laboratory and crossed to produce *Bptf*^*f/f*^;*Mx1*-cre mice and control littermates. To induce *Bptf* knockout in the BM, we injected 2- to 3-month-old mice with pIpC (Sigma) three times every other day. UNC-Chapel Hill Institutional Animal Care and Use Committee approved all animal experiments.

RNA-Seq {#sec4.2}
-------

RNA was extracted from sorted LSK cells with the picoRNA Kit (Applied Biosystems) and the RNA-seq library was prepared with Illumina kits according to the manufacturer's protocol, followed by deep sequencing.
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